Helix Therapeutics, a biotech startup developing treatments for infectious and genetic diseases, has reeled in a $515,000 investment from quasi-public investor Connecticut Innovations, according to Connecticut Innovations. The investment is part of a $965,000 round of financing that included Cambridge, MA-based investment firm LaunchCapital, individual backers, and a line of credit from Webster Bank. Helix is developing treatments made of small pieces of DNA to treat illnesses such as AIDS/HIV, sickle cell anemia, and Gaucher’s disease. The firm’s drugs, licensed from Yale University School of Medicine, aim to treat diseases by binding to DNA in human cells and permanently modifying genes, the firm says.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
